Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Files An 8-K Other Events
Item8.01 Other Events.
On March20, 2017, Five Prime Therapeutics, Inc. (the Company)
issued a press release announcing the appointment of Helen
Collins, M.D., as Senior Vice President and Chief Medical
Officer, effective immediately, following the transition of
Robert Sikorski, M.D., Ph.D., to the position of Senior Vice
President, Special Projects.
A copy of the press release is filed herewith as Exhibit 99.1 and
the information contained therein is incorporated by reference
into this Current Report on Form 8-K.
Item9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
ExhibitNo. |
Description |
|
| 99.1 | Press Release, dated March 20, 2017. |
2
About Five Prime Therapeutics, Inc. (NASDAQ:FPRX)
Five Prime Therapeutics, Inc. (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company has three product candidates in clinical development covering multiple potential indications. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations. The Company seeks to engage third-party collaborators to assist it in developing companion diagnostics for its clinical programs. The Company’s product candidates include FPA008, FPA144 and FP-1039/GSK3052230. The FPA008 is an antibody that inhibits colony stimulating factor-1 (CSF1), receptor (CSF1R). The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b (FGFR2b). FP-1039 is a protein therapeutic designed to trap and neutralize cancer-promoting fibroblast growth factors (FGFs). Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Recent Trading Information
Five Prime Therapeutics, Inc. (NASDAQ:FPRX) closed its last trading session up +0.30 at 39.21 with 375,367 shares trading hands.